Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus platinum-based doublet neoadjuvant conversion therapy in unresectable stage IIIB/IIIC NSCLC
ChiCTR2600126301Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Surgical Resection Rate and R0 Resection Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600126301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126301.